CA2370401A1 - Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant - Google Patents

Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant Download PDF

Info

Publication number
CA2370401A1
CA2370401A1 CA002370401A CA2370401A CA2370401A1 CA 2370401 A1 CA2370401 A1 CA 2370401A1 CA 002370401 A CA002370401 A CA 002370401A CA 2370401 A CA2370401 A CA 2370401A CA 2370401 A1 CA2370401 A1 CA 2370401A1
Authority
CA
Canada
Prior art keywords
phenoxazin
ethoxy
phenyl
ethoxypropanoic acid
arginine salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370401A
Other languages
English (en)
Inventor
Om Reddy Gaddam
Rajender Kumar Potlapally
Raju Sirisilla
Vyas Krishnamurthi
Sreenivasa Rao Dharmaraja
Ramabhadra Sarma Mamillapalli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Dr Reddys Research Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/IB1999/000681 external-priority patent/WO2000063191A1/fr
Application filed by Dr Reddys Research Foundation filed Critical Dr Reddys Research Foundation
Publication of CA2370401A1 publication Critical patent/CA2370401A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
    • C07D265/34—1,4-Oxazines; Hydrogenated 1,4-oxazines condensed with carbocyclic rings
    • C07D265/38—[b, e]-condensed with two six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

L'invention concerne de nouvelles formes polymorphes/pseudompolymorphes d'un sel arginine d'acide 3-[4-[2-(phénoxazine-10-yl)éthoxy]phényl]-2-éthoxypropanoïque de formule (I). L'invention concerne aussi une composition pharmaceutique comprenant les nouvelles formes polymorphes ou leur mélange et un support pharmaceutiquement acceptable. Les formes polymorphes sont plus actives comme agent antidiabétique et hypolipidémique que le nouvel acide 3-[4-[2-(phénoxazin-10-yl)éthoxy]phényl]-2-éthoxypropanoïque.
CA002370401A 1999-04-16 2000-04-17 Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant Abandoned CA2370401A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/IB1999/000681 WO2000063191A1 (fr) 1999-04-16 1999-04-16 Nouvelles formes polymorphes d'un agent antidiabetique: procede de preparation et composition pharmaceutique contenant ces dernieres
IBPCT/IB99/00681 1999-04-16
IN436/MAS/99 1999-04-19
IN436MA1999 1999-04-19
PCT/IB2000/000470 WO2000063192A1 (fr) 1999-04-16 2000-04-17 Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant

Publications (1)

Publication Number Publication Date
CA2370401A1 true CA2370401A1 (fr) 2000-10-26

Family

ID=26318745

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370401A Abandoned CA2370401A1 (fr) 1999-04-16 2000-04-17 Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant

Country Status (17)

Country Link
EP (1) EP1171430A1 (fr)
CN (1) CN1351597A (fr)
AU (1) AU3831300A (fr)
BG (1) BG106022A (fr)
BR (1) BR0010683A (fr)
CA (1) CA2370401A1 (fr)
CZ (1) CZ20013711A3 (fr)
EE (1) EE200100529A (fr)
HR (1) HRP20010748A2 (fr)
HU (1) HUP0200758A3 (fr)
IL (1) IL145958A0 (fr)
MX (1) MXPA01010472A (fr)
NO (1) NO20015016L (fr)
PL (1) PL351492A1 (fr)
RU (1) RU2001130883A (fr)
TR (1) TR200103851T2 (fr)
WO (1) WO2000063192A1 (fr)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1263458B1 (fr) 2000-03-08 2005-11-16 Novo Nordisk A/S Reduction du cholesterol seriques
US6897199B2 (en) * 2001-02-05 2005-05-24 Dr. Reddy's Laboratories Ltd. Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
JP4563675B2 (ja) 2001-10-12 2010-10-13 ハイ・ポイント・ファーマスーティカルズ、エルエルシー 置換ピペリジン類、およびヒスタミンｈ３受容体関連疾患の治療のためのその使用
JP2005518391A (ja) 2001-12-21 2005-06-23 ノボ　ノルディスク　アクティーゼルスカブ Ｇｋ活性化剤としてのアミド誘導体
AU2002255017B2 (en) * 2002-04-19 2008-11-13 Faes Farma, S.A. Polymorph of 4-[2-[4-[1-(2-ethoxyethyl)-1H-benzimidazole-2-yl]-1-piperidinyl]ethyl]-alpha, alpha-dimethyl-benzeneacetic acid
CA2744893A1 (fr) 2002-06-27 2004-01-08 Novo Nordisk A/S Derives d'arylcarbonyle servant d'activateurs de glucokinase
EP1625112B1 (fr) 2003-05-14 2009-07-22 High Point Pharmaceuticals, LLC Nouveaux composes pour le traitement de l'obesite
AU2004275928B2 (en) 2003-09-30 2010-03-11 Novo Nordisk A/S Melanocortin receptor agonists
EP2298337B1 (fr) 2003-12-09 2017-02-22 Novo Nordisk A/S Régulation des préférences alimentaires en utilisant des agonistes du GLP-1
CA2551324C (fr) 2004-01-06 2012-11-27 Novo Nordisk A/S Heteroaryl-urees et leur utilisation en tant qu'activateurs de glucokinase
WO2005105785A2 (fr) 2004-05-04 2005-11-10 Novo Nordisk A/S Nouveaux derives d'indole
US8410047B2 (en) 2004-06-11 2013-04-02 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
ES2391776T3 (es) 2004-11-22 2012-11-29 Novo Nordisk A/S Formulaciones solubles, estables conteniendo insulina con una sal de protamina
KR101066882B1 (ko) 2004-12-03 2011-09-26 트랜스테크 파르마, 인크. 헤테로방향족 글루코키나제 활성화제
ATE536344T1 (de) 2005-07-04 2011-12-15 High Point Pharmaceuticals Llc Histamine h3 receptor antagonisten
AU2006268589B2 (en) 2005-07-14 2011-09-29 Vtv Therapeutics Llc Urea glucokinase activators
EP1910317B1 (fr) 2005-07-20 2013-07-03 Eli Lilly And Company Composés joints en position 1-amino
PL1951658T3 (pl) 2005-11-17 2013-02-28 Lilly Co Eli Antagoniści receptora glukagonu, preparatyka i zastosowania terapeutyczne
ES2388681T3 (es) 2006-03-28 2012-10-17 High Point Pharmaceuticals, Llc Benzotiazoles con actividad de los receptores de histamina H3
PL2079732T3 (pl) 2006-05-29 2012-05-31 High Point Pharmaceuticals Llc 3-(1,3-benzodioksol-5-ylo)-6-(4-cyklopropylopiperazyn-1-ylo)-pirydazyna, jej sole i solwaty oraz jej zastosowanie jako antagonisty receptora histaminowego h3
EP2086951B1 (fr) 2006-11-15 2011-12-21 High Point Pharmaceuticals, LLC Nouvelles 2-(2-hydroxyphényl) benzothiadiazines utilisées pour traiter l'obésité et le diabète
WO2008059026A1 (fr) 2006-11-15 2008-05-22 High Point Pharmaceuticals, Llc Nouveaux 2-(2-hydroxyphényl)benzimidazoles utilisés pour traiter l'obésité et le diabète
EP2099777B1 (fr) 2007-01-11 2015-08-12 Novo Nordisk A/S Activateurs de l'urée glucokinase
JP2010013472A (ja) * 2009-09-09 2010-01-21 Faes Farma Sa ４−［２−［１−（２−エトキシエチル）−１Ｈ−ベンズイミダゾール−２−イル］−１−ピペリジニル］エチル］−α，α−ジメチルベンゼノ酢酸の多形体
BR112012021231A2 (pt) 2010-02-26 2015-09-08 Basf Plant Science Co Gmbh método para acentuar o rendimento em plantas, planta, construto, uso de um construto, método para a produção de uma planta transgênica, partes coletáveis de uma planta, produtos derivados de uma planta, uso de um ácido nucleíco e método para a produção de um produto
US20130012432A1 (en) 2010-02-26 2013-01-10 Novo Nordisk A/S Peptides for Treatment of Obesity
CA2792663A1 (fr) 2010-03-26 2011-09-29 Novo Nordisk A/S Nouveaux analogues du glucagon
WO2012104834A1 (fr) 2011-02-03 2012-08-09 Pharmedica Ltd. Nouveaux films à dissolution orale pour administration d'insuline, pour traitement du diabète
AU2012234276A1 (en) 2011-03-28 2013-08-29 Novo Nordisk A/S Novel glucagon analogues
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
US20150004144A1 (en) 2011-12-02 2015-01-01 The General Hospital Corporation Differentiation into brown adipocytes
RS59124B1 (sr) 2013-04-18 2019-09-30 Novo Nordisk As Stabilni, produženi koagonisti glp-1/glukagonskih receptora za medicinsku upotrebu
EP3151852A1 (fr) 2014-06-04 2017-04-12 Novo Nordisk A/S Co-agonistes de récepteur du glucagon/glp-1 à usage médical
CN111032680A (zh) 2017-03-15 2020-04-17 诺和诺德股份有限公司 能够与黑皮质素4受体结合的双环化合物
US20210221867A1 (en) 2018-05-15 2021-07-22 Novo Nordisk A/S Compounds Capable of Binding to Melanocortin 4 Receptor
WO2020053414A1 (fr) 2018-09-14 2020-03-19 Novo Nordisk A/S Composés bicycliques aptes à se lier aux agonistes du récepteur de la mélanocortine 4

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
US5248699A (en) * 1992-08-13 1993-09-28 Pfizer Inc. Sertraline polymorph
IN182496B (fr) * 1996-02-20 1999-04-17 Reddy Research Foundation
WO1997027191A1 (fr) * 1996-06-19 1997-07-31 Dr. Reddy's Research Foundation Nouvelles formes polymorphes de la troglitazone ayant une activite anti-diabetique augmentee et procede pour leur preparation
GB9604242D0 (en) * 1996-02-28 1996-05-01 Glaxo Wellcome Inc Chemical compounds
FR2746099B1 (fr) * 1996-03-13 1998-04-30 Procede ameliore pour la preparation de derives de l'acide 3-(10-phenothiazyl)-propanoique ou 3-(10-phenoxazyl)-propanoique
WO1999019313A1 (fr) * 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Nouveaux composes tricycliques et leur utilisation en medecine, procede de preparation de ces derniers et compositions pharmaceutiques les contenant
EP1051403A1 (fr) * 1998-01-29 2000-11-15 Dr. Reddy's Research Foundation Nouveaux acides alcanoiques et leur utilisation en medecine, leur procede de preparation et compositions pharmaceutiques les contenant
NZ504106A (en) * 1998-05-27 2003-02-28 Dr Fused Oxazine, Thiazine and pipyridine compounds, process for their preparation and pharmaceutical compositions containing them

Also Published As

Publication number Publication date
BG106022A (bg) 2002-04-30
IL145958A0 (en) 2002-07-25
PL351492A1 (en) 2003-04-22
NO20015016L (no) 2001-12-11
EE200100529A (et) 2002-12-16
CN1351597A (zh) 2002-05-29
HUP0200758A3 (en) 2003-07-28
RU2001130883A (ru) 2004-03-20
CZ20013711A3 (cs) 2002-07-17
NO20015016D0 (no) 2001-10-15
TR200103851T2 (tr) 2002-04-22
AU3831300A (en) 2000-11-02
HRP20010748A2 (en) 2003-02-28
EP1171430A1 (fr) 2002-01-16
MXPA01010472A (es) 2002-05-06
BR0010683A (pt) 2003-07-01
HUP0200758A2 (hu) 2002-07-29
WO2000063192A1 (fr) 2000-10-26

Similar Documents

Publication Publication Date Title
CA2370401A1 (fr) Nouvelles formes polymorphes d'un agent antidiabetique, leur procede de preparation et compositions pharmaceutiques les renfermant
JP2003508348A (ja) 新規多型形態の抗糖尿病薬剤：それらの製造方法およびそれらを含有する医薬組成物
WO2000063193A1 (fr) Nouvelles formes polymorphes d'un agent antidiabetique: leur procede de preparation et composition pharmaceutique contenant lesdites formes
CA2426117A1 (fr) Nouvelles formes polymorphes de 5-[4-[2-[n-methyl-n-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate et procede de preparation associe
US6528507B1 (en) Polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
WO2002028857A1 (fr) Polymorphes de chlorhydrates de pioglitazone et leur utilisation en tant qu'antidiabetiques
US20040068116A1 (en) Novel polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
US6897199B2 (en) Pharmaceutically acceptable salts of phenoxazine and phenothiazine compounds
WO2002062798A2 (fr) Sels de composes heterocycliques pharmaceutiquement acceptables
US20020169175A1 (en) Pharmaceutically acceptable salts of heterocyclic compounds
EP1623984A1 (fr) Polymorphe I du sel de potassium de 5-[4-[[3-methyle-4-oxo-3,4-dihydroquinazoline-2yl]methoxy]benzyle]thiazolidine-2,4-dione
WO2002030914A1 (fr) Sels de derives de benzothiazine et de benzoxazine et compositions pharmaceutiques a base de ces sels
AU2001291232A1 (en) Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
AU2001291232B2 (en) Novel polymorphic forms of 5-[4-[2-[N-methyl-N-(2-pyridyl)amino]ethoxy]benzyl] thiazolidine-2,4-dione maleate and process for their preparation
WO2003066612A1 (fr) Nouvelles formes polymorphes d'agents bicycliques antidiabetiques, leur procede de preparation et compositions pharmaceutiques les contenant
WO2003006022A1 (fr) Derives de tetrahydroquinoline et leur utilisation en medecine, procede de preparation associe et compositions pharmaceutiques contenant lesdits composes

Legal Events

Date Code Title Description
FZDE Discontinued